Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors

被引：37
|
作者：
Zettl, Heiko [1 ]
Schubert-Zsilavecz, Manfred [1 ]
Steinhilber, Dieter [1 ]
机构：
[1] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60438 Frankfurt, Germany
来源：
CHEMMEDCHEM | 2010年 / 5卷 / 02期
关键词：
DPP-4; inhibitors; drug discovery; incretin mimetics; medicinal chemistry; DIPEPTIDYL-PEPTIDASE-IV; GLUCAGON-LIKE PEPTIDE-1; TYPE-2; DIABETES-MELLITUS; ANTIHYPERGLYCEMIC PROPERTIES; HEALTHY-VOLUNTEERS; RECEPTOR AGONISTS; CRYSTAL-STRUCTURE; POTENT; PHARMACOKINETICS; PHARMACODYNAMICS;
D O I：
10.1002/cmdc.200900448
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：179 / 185
页数：7
相关论文
共 50 条
  • [41] DPP-4 inhibitors and angioedema: a cause for concern?
    Byrd, Jennifer S.
    Minor, Deborah S.
    Elsayed, Raghda
    Marshall, Gallen D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 106 (05) : 436 - 438
  • [42] Indications for incretin-based therapies of type 2 diabetes: An evaluation of study populations, study design and effectiveness of exenatide and DPP-4 inhibitors in clinical studies
    Bachmann, O. P.
    Kazda, C.
    Gallwitz, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2007, 2 (05) : 315 - 320
  • [43] Molecular dynamic simulations reveal the mechanism of binding between xanthine inhibitors and DPP-4
    Gu, Yongliang
    Wang, Wei
    Zhu, Xiaolei
    Dong, Keke
    JOURNAL OF MOLECULAR MODELING, 2014, 20 (02)
  • [44] Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
    Sharma, Ashwani
    Virmani, Tarun
    Sharma, Anjali
    Chhabra, Vaishnavi
    Kumar, Girish
    Pathak, Kamla
    Alhalmi, Abdulsalam
    DIABETES METABOLIC SYNDROME AND OBESITY, 2022, 15 : 1845 - 1864
  • [45] Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
    S., Ametov A.
    Karpova, E., V
    DIABETES MELLITUS, 2010, 13 (02): : 69 - 75
  • [46] DPP-4 inhibitors for treating T2DM-hype or hope? an analysis based on the current literature
    Saini, Kunika
    Sharma, Smriti
    Khan, Yousuf
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2023, 10
  • [47] Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
    Geetha, K.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2022, 13 (01) : 99 - 101
  • [48] Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications
    Kalra, Sanjay
    Unnikrishnan, Ambika G.
    Agrawal, Navneet
    Singh, Anupam K.
    RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2011, 5 (03) : 197 - 202
  • [49] Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors
    Fiorentino, Teresa Vanessa
    Sesti, Giorgio
    ENDOCRINE, 2016, 53 (02) : 373 - 380
  • [50] A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin
    Wu, Nan
    An, Guohua
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (01) : 278 - 289
12345